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Abstract
Background
We evaluated optimal duration of dual antiplatelet therapy (DAPT) after second-generation
drug-eluting stent (DES) implantation in acute coronary syndrome (ACS).
Material and methods
From pooled analysis of three randomized clinical trials (EXCELLENT, IVUS-XPL, RESET),
a total of 2,216 patient with ACS undergoing second-generation DES implantation were
selected. Each study randomized patients to a short-duration DAPT arm (n = 1119;�6
months) or a standard-duration DAPT arm (n = 1097;�12 months). Two-thirds of patients
were male, and their mean age was 63 years. Mean DAPT durations were 164 ±76 and 359
±68 days, respectively. The primary endpoint was composite of cardiac death, myocardial
infarction, stent thrombosis, stroke or major bleeding during the first 12 months after implan-
tation, analyzed according to the intention-to-treat population.
Results
Demographic characteristics were balanced between groups. Mean DAPT duration was
164 and 359 days, respectively. Primary endpoint occurred in 22 patients with short-DAPT
and 21 patients with standard-DAPT (2.0% versus 1.9%; hazard ratio [HR] 1.03; 95% confi-
dence interval [CI] 0.56–1.86; p = 0.94). Landmark analysis after six-months, no significant
difference in primary endpoint between short and standard duration DAPT (1.0% versus
0.8%; HR 1.22; 95% CI 0.51–2.95; p = 0.66).
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Conclusions
Short-duration DAPT (�6 months) demonstrated a similar incidence of net adverse cardio-
vascular and clinical events at 12 months after second-generation DES in ACS compared
with standard duration DAPT (�12 months).
Clinical trial registration
EXCELLENT (ClinicalTrials.gov, NCT00698607), RESET (ClinicalTrials.gov,
NCT01145079), IVUS-XPL (ClinicalTrials.gov, NCT01308281)
Introduction
Dual antiplatelet therapy (DAPT) after drug-eluting stent (DES) implantation has become
standard therapy. [1] The optimal duration of DAPT recommended for first-generation DESs
was at least 12 months, but recent studies demonstrated short-duration (�6 months) DAPT
show non-inferior efficacy and safety compared to longer-duration (�12 months) DAPT in
patients with second-generation DESs. [2–6] Based on these studies, 6 months of DAPT is
now considered a reasonable approach in patients with stable angina receiving second-genera-
tion DESs.
By contrast, recommendations for the optimal duration of DAPT have not changed for
patients with acute coronary syndrome (ACS), even with the use of second-generation DESs,
as data to support recommendation modifications are lacking. ACS is well known to increase
the risk of recurrent ischemic events, and a standard duration of DAPT (�12 months) may
help prevent these events. A recent meta-analysis suggested that the net clinical benefit of dif-
ferent DAPT durations might vary according to the clinical presentation. [7] However, sec-
ond-generation DESs were reported to attenuate the benefit of a standard duration of DAPT
compared to short-duration (�6 months) DAPT. [8]
Data are currently limited regarding differences in clinical outcome between short-duration
and standard-duration DAPT after second-generation DES implantation in the ACS popula-
tion. Therefore, we performed pooled analysis of three randomized trials to investigate the
efficacy and safety of short-duration (�6 months) compared with standard-duration (�12
months) of DAPT after second-generation DES implantation in patients with ACS.
Materials and methods
Study design
This is a patient-level pooled analysis of data from three multicenter, prospective, open-label,
randomized trials comparing short-duration (�6 months) and standard-duration (�12
months) DAPT. Each study protocol was previously described. [5, 6, 9] Briefly, the EXCEL-
LENT trial enrolled 1,443 patients with at least 1 de novo lesion treated with an everolimus or
first-generation sirolimus DES. [5] The RESET trial enrolled 2,117 patients who were ran-
domly assigned in a 1:1 ratio to receive either an Endeavor zotarolimus DES with 3 months of
DAPT or a Resolute zotarolimus DES, everolimus DES, or first-generation sirolimus DES with
12 months of DAPT. [6] The IVUS-XPL trial included 1,400 patients who underwent everoli-
mus DES implantation for long coronary lesions (implanted stent length�28 mm). [9] The
patients were randomly assigned to treatments using a 2 x 2 factorial design according to
DAPT duration (6-month vs. 12-month) and whether intravascular ultrasound was used.
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In the three trials, ACS was defined as a clinical syndrome consisting of unstable angina,
non-ST-elevation myocardial infarction (MI), or ST-elevation MI, diagnosed by clinical pre-
sentation, electrocardiogram, or cardiac enzymes. The second-generation DESs were the Reso-
lute zotarolimus DES, everolimus DES, or Endeavor zotarolimus DES. Clopidogrel was the
only P2Y12 receptor antagonist used in the DAPT regimens in all studies.
Study population. The study population included 2,216 patients with ACS: 568 patients
from the EXCELLENT trial, 686 patients from the IVUS-XPL trial, and 962 patients from the
RESET trial. There were 1,119 patients in the short-duration DAPT arm and 1,097 in the stan-
dard-duration DAPT arm (Fig 1).
Study endpoints
The primary endpoint was composite of cardiac death, MI, stent thrombosis, stroke or major
bleeding as net adverse cardiovascular and clinical events during the 12-month period after
randomization. Secondary endpoints were composite of cardiac death, MI or stent thrombosis
and each component of primary endpoint. Clinical events were defined according to recom-
mendations of the Academic Research Consortium. [10] All deaths were considered cardiac
deaths unless a definite non-cardiac cause was established. MI was defined as the presence of
clinical signs of MI plus a creatine kinase-MB fraction or troponin T or I increase to above the
upper limit of normal. Target vessel revascularization (TVR) was defined as ischemic driven
repeat revascularization of the treated vessel by percutaneous coronary intervention (PCI) or
bypass surgery. Stent thrombosis was defined as definite or probable stent thrombosis accord-
ing to the Academic Research Consortium classification. According to the Thrombolysis in
Myocardial Infarction (TIMI) criteria, major bleeding was defined as overt clinical bleeding.
Stroke was defined according to the definition used in each trial.
Statistical analysis
Patient-level data were obtained from the principal investigators of each trial. Individual
patient data were pooled in a single dataset and analyzed with a single-stage approach. We
used the intention-to-treat population for the analyses, with all patients considered according
to the treatment arm to which they were randomly assigned. Continuous variables are pre-
sented as mean (standard deviation [SD]) and compared using the Student’s t-test. Categorical
variables are presented as count (percentage) and compared using χ2 test for contingency table
with at least five expected cases for cell, or by Fisher exact test for contingency table with fewer
than five expected cases for cell. Cumulative event rates were estimated using the Kaplan-
Meier method, and survival curves were compared using the log-rank test. Hazard ratios
(HRs) with 95% confidence intervals (CIs) were estimated using the Cox proportional hazards
method. To minimize bias by including events in the early post-implantation period, landmark
analysis for primary endpoint was performed with a landmark of clopidogrel discontinuation
at 6 months among patients who were event-free at 6 months (3 months in the RESET trial)
with intention to treated analysis.
The consistency of treatment effect in pre-specified subgroups was assessed using Cox
regression models with tests for interaction. We applied the DAPT score [11], PRECISE
DAPT score [12] and Creatinine Clearance Estimate by Cockcroft-Gault Equation to the study
population: DAPT score�2, Risk groups based on PRECISE DAPT score, and Creatinine
clearance� 60ml/min. A two-sided P-value <0.05 was considered significant. All analyses
were performed using SAS version 9.2 (SAS Institute, Cary, NC).
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Results
Baseline characteristics
Of the 2,216 patients, 1,119 were allocated to receive short-duration DAPT and 1,097 to
receive standard-duration DAPT. Mean DAPT durations were 164 ±76 and 359 ±68 days for
the two groups. Baseline clinical characteristics of the groups were well balanced (Table 1).
Mean age of the entire population was 62.5 ±10.1 years. One-third of the study population pre-
sented with an acute MI. The standard-duration DAPT group had a higher number of stents
per patient and greater total stent length than the short-duration DAPT group.
Primary and secondary endpoints
Primary endpoints occurred in 22 patients with short-duration DAPT group and 21 patients
in standard duration DAPT group (2.0% vs. 1.9%; HR for short-duration DAPT 1.03; 95% CI
0.56–1.86; p = 0.94; Table 2, Fig 2). This result appeared consistently through each trial without
heterogeneity (S1 Fig). Landmark analysis at 6 months showed no difference in event rate
within 6-month (1.0% vs. 1.1%; HR 0.90; 95% CI 0.40–2.04; p = 0.80) and after 6-months from
randomization (1.0% vs. 0.8%; HR 1.22; 95% CI 0.51–2.95; p = 0.66). Composite of cardiac
death, MI or stent thrombosis also did not differ according to DAPT duration (1.3% vs. 1.1%;
HR 1.23; 95% CI 0.57–2.62; p = 0.60).
For individual endpoints, the percentages of death, MI, and stent thrombosis were 0.8%,
0.6%, and 0.5% for the short-duration DAPT arm and 1.0%, 0.5%, and 0.4% for the standard-
duration DAPT arm (Table 2). Ischemia-driven TVR was required in 45 patients (4.0%) in the
short-duration DAPT arm and 26 patients (2.4%) in the standard-duration DAPT arm (HR
1.73; 95% CI 1.07–2.81; p = 0.03). There was no difference in major bleeding between groups
(0.4% vs. 0.5%; HR 0.65; 95% CI 0.18–2.30; p = 0.50).
Fig 1. Study profile. From three multicenter, prospective, open-label, randomized trials, a total of 2,216 patients with ACS
undergoing second-generation DES implantation divided into short-duration (n = 1119;�6 months) and standard-duration
(n = 1097;�12 months).
https://doi.org/10.1371/journal.pone.0207386.g001
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Table 1. Clinical and Angiographic characteristics.
Characteristics Short DAPT (n = 1119) Standard DAPT (n = 1097) P
Clinical variables
DAPT duration, day 164 ± 76 359 ± 68 <0.001
Age, years 62.7 ± 9.7 62.3 ± 10.5 0.349
Male sex 728 (65.1) 741 (67.5) 0.225
Diabetes mellitus 363 (32.4) 360 (32.8) 0.856
Hypertension 705 (63.0) 675 (61.5) 0.483
Dyslipidemia 721 (64.4) 712 (64.9) 0.824
Congestive heart failure 79 (7.1) 76 (6.9) 0.950
Current smoker 320 (28.6) 294 (26.8) 0.481
Clinical presentation at index procedure 0.629
Unstable angina 815 (72.8) 791 (72.1)
Non ST-elevation MI 262 (23.4) 271 (24.7)
ST-elevation MI 42 (3.8) 35 (3.2)
Prior PCI 72 (6.4) 77 (7.0) 0.611
Prior MI 51 (4.6) 34 (3.1) 0.077
LVEF, % 61.2 ± 10.3 61.7 ± 9.8 0.245
DAPT score�2� 335 (29.9) 325 (29.6) 0.889
PRECISE DAPT score† groups (n = 2181) 0.181
Very low 343 (31.2) 377 (34.9)
Low 398 (36.1) 357 (33.1)
Moderate 215 (19.5) 194 (18.0)
High 145 (13.2) 152 (14.1)
Angiographic variables
No. of diseased vessels 0.951
1 526 (47.0) 510 (46.5)
2 350 (31.3) 343 (31.3)
3 243 (21.7) 244 (22.2)
Stent type
Everolimus-eluting stents 630 (56.3) 749 (68.3)
Endeavor zotarolimus-eluting stents 489 (43.7) 0 (0)
Resolute zotarolimus-eluting stents 0 (0) 348 (31.7)
ACC/AHA class B2/C 809 (72.7) 805 (73.8) 0.564
IVUS-guided implantation 524 (46.8) 512 (46.7) 0.966
No. of stents per patient 1.46 ± 0.72 1.54 ± 0.79 0.015
Stent diameter <3.0 mm 413 (37.1) 406 (37.2) 0.965
Long lesion (�28 mm) 435 (38.9) 483 (44.1) 0.016
Total stent length, mm 34.2 ±18.1 36.9 ± 20.3 0.001
Medications at discharge
Aspirin 1105 (98.7) 1078 (98.3) 0.572
Clopidogrel 1089 (97.3) 1076 (98.1) 0.201
Beta blocker 770 (68.8) 767 (69.9) 0.676
ACE inhibitor 431 (38.5) 439 (40.0) 0.725
Angiotensin II receptor blocker 330 (29.5) 291 (26.5) 0.258
(Continued)
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Subgroup analyses
In patients with MI, although overall incidence of primary endpoints was higher than
total group, there was also no difference in primary endpoint (2.6% vs. 2.6%; HR 1.01; 95%
CI 0.38–2.69; p = 0.98) and each individual endpoint between two groups (S1 Table). Land-
mark analysis at 6 months showed no difference (0.7% vs. 0.7%; HR 1.01; 95% CI 0.14–7.19;
p = 0.99).
In pre-specified subgroup analyses, standard duration of DAPT therapy increased primary
endpoint within chronic kidney disease (creatinine clearance� 60mL/min) group compared
to short duration of DAPT. there was a significant interaction for the chronic kidney disease
and duration of DAPT (p for interaction = 0.04, Fig 3).
By contrast, in ‘Very low’ risk group based on PRECISE-DAPT score, standard DAPT ther-
apy showed lower primary endpoint than short DAPT therapy. Other PRECISE-DAPT risk
group did not showed any difference. There was a trend of interaction for PRECISE-DAPT
risk groups and duration of DAPT. (Fig 3, S2 Table).
Table 1. (Continued)
Characteristics Short DAPT (n = 1119) Standard DAPT (n = 1097) P
Statin 1006 (89.9) 958(87.3) 0.154
Data are number (%) or mean ± standard deviation. ACC indicates American College of Cardiology; ACE, angiotensin-converting enzyme; AHA, American Heart
Association; CHF, congestive heart failure; IVUS, intravascular ultrasound; LVEF, left ventricular ejection fraction; MI, myocardial infarction; PCI, percutaneous
coronary intervention.
�DAPT score was based on the DAPT trial. [11]
† PRECISE DAPT score based on web calculator of PRECISE DAPT. [12]
https://doi.org/10.1371/journal.pone.0207386.t001
Table 2. Clinical outcomes during the first 12 months.
Short
DAPT (n = 1119)
Standard DAPT (n = 1097) HR (95% CI) � P
Primary endpoint† 22 (2.0) 21(1.9) 1.03 (0.56–1.86) 0.937
<6 months 11 (1.0) 12 (1.1) 0.90 (0.40–2.04) 0.798
�6 months 11 (1.0) 9 (0.8) 1.22 (0.51–2.95) 0.657
Cardiac death, MI, or ST 15 (1.3) 12 (1.1) 1.23 (0.57–2.62) 0.600
<6 months 8 (0.7) 10 (0.9) 0.78 (0.31–1.99) 0.609
�6 months 7 (0.7) 2 (0.2) 3.43 (0.71–16.5) 0.120
All-cause death 9 (0.8) 11 (1.0) 0.80 (0.33–1.92) 0.610
Cardiac death 5 (0.4) 6 (0.5) 0.82 (0.25–2.67) 0.736
MI 7 (0.6) 5 (0.5) 1.37 (0.44–4.32) 0.591
ST 6 (0.5) 4 (0.4) 1.47 (0.42–5.22) 0.549
TVR 45 (4.0) 26 (2.4) 1.73 (1.07–2.81) 0.026
Stroke 3 (0.3) 5 (0.5) 0.58 (0.14–2.44) 0.461
Minor or major bleeding 9 (0.8) 14 (1.3) 0.63 (0.27–1.45) 0.274
Major Bleeding ‡ 4 (0.4) 6 (0.5) 0.65 (0.18–2.30) 0.503
Data are number (%). CI indicates confidence interval; HR, hazard ratio; ST, stent thrombosis; TVR, target vessel revascularization
� HRs are for short-duration DAPT vs. standard-duration DAPT groups
† Primary endpoint was composite of Cardiac death, MI, ST, stroke or major bleeding.
‡ Major bleeding according to Thrombolysis in Myocardial Infarction criteria.
https://doi.org/10.1371/journal.pone.0207386.t002
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Discussion
In this pooled analysis involving patients with ACS, there is no difference in incidence of net
adverse cardiovascular and clinical events (composite of cardiac death, MI, stent thrombosis,
stroke or major bleeding) at 12 months after second-generation DES implantation between
short (�6 months) and standard-duration DAPT (�12 months). However, TVR increased
with short-duration DAPT compared with standard duration DAPT.
DAPT duration in DES area
Although early DESs reduced in-stent restenosis rate compared with bare metal stents, the
concern arose that DESs may have a higher incidence of late and very late stent thrombosis.
[13] Early discontinuation of DAPT was associated with thrombotic complications in observa-
tional studies of first-generation DESs. [14] These concerns reinforced recommendations for
longer-duration DAPT after DES implantation.
However, second-generation DESs, with their reduced strut thickness, biocompatible poly-
mer, and appropriate drug dose, has been shown to improve stent strut coverage, reducing
stent thrombosis. [15] In the DAPT (Dual Antiplatelet Therapy) trial, a significant interaction
was observed between DAPT duration (30 vs. 12 months) and DES type for major adverse car-
diovascular and cerebrovascular events (p = 0.048). [16] Moreover, a previous meta-analysis
Fig 2. Kaplan-Meier survival curves for the primary and secondary endpoint. (A) primary endpoints (Composite of death, MI, stent thrombosis,
stroke or major bleeding) in patient with ACS. (B) landmark analysis after 6 months. (3 months for RESET). (C) Composite of death, MI, stent
thrombosis. (D) Target vessel revascularization.
https://doi.org/10.1371/journal.pone.0207386.g002
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demonstrated that the higher risk of stent thrombosis with short-term DAPT was attenuated
with second-generation DESs. [8]
Previous studies
Several randomized studies compared the safety and efficacy of short-term (�6 months) ver-
sus long-term (�12 months) DAPT after second-generation DES implantation. The ITALIC
trial showed no difference in the primary endpoint (composite of cardiac death, MI, stroke,
TVR, or major bleeding) at 12 months between 6-month and 24-month DAPT after everoli-
mus eluting DES implantation. [17] The TVR was higher with 6-month DAPT, although the
difference did not reach statistical significance. Notable, the ITALIC trial enrolled primarily
low-risk patients; most had stable angina, and only a limited number had ACS. The OPTI-
MIZE trial demonstrated that 3-month DAPT in patients with stable angina and low-risk ACS
was associated with a similar rate of major adverse cardiac events (composite of all-cause
death, MI or TVR) compared with 12-month DAPT. [4] It also showed non-inferiority of
short-duration DAPT compared with 12-month DAPT for firm endpoints, such as the com-
posite of all-cause death, MI, stroke, or major bleeding. Recently, the SECURITY trial tested
the non-inferiority of 6-month DAPT in patients with stable angina and unstable angina fol-
lowing the implantation of various second-generation DESs. [3] The composite of cardiac
death, MI, stroke, stent thrombosis, or major bleeding did not differ between groups. Although
Fig 3. Subgroup analyses of the primary endpoint.
�
DAPT score was from the DAPT trial. [11] † PRECISE DAPT score based on
web calculator of PRECISE DAPT;http://www.precisedaptscore.com/ [12]. DM, diabetes mellitus; GFR, glomerular filtration rate.
https://doi.org/10.1371/journal.pone.0207386.g003
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previous studies showed consistent non-inferiority of short-duration (�6 months) compared
to standard duration (�12 months) DAPT with second-generation DESs, these results may
not be applicable to high-risk populations because most of the studies included patients with
stable angina and a low percentage with ACS.
Short DAPT duration in ACS with second generation DES
ACS itself is a risk factor for future thrombotic cardiovascular events, and 12 months of DAPT
has been recommended in practice. [1] However, potent antiplatelet therapy increases the risk
of bleeding complications. A recent meta-analysis of 11,473 patients receiving a DES indicated
that the benefits of different DAPT durations varied according to clinical presentation. [10] In
ACS patients, short-duration (�6 months) DAPT showed a higher trend in 1-year rate of MI
or stent thrombosis compared with standard duration (�12 months) DAPT (2.43% vs. 1.67%;
p = 0.06). Conversely, MI or stent thrombosis rates were comparable between DAPT groups in
patients with stable angina (1.67% vs. 1.79%; p = 0.72). Recent SMART-DATE trial evaluating
short-duration DAPT after second-generation DES implantation in ACS showed non-inferi-
ority of short-duration DAPT in composite of all-cause death, MI or stroke at 18 months. [18]
However, there was an increased incidence of MI in short-duration DAPT. These results sug-
gested that an individualized DAPT regimen and duration are needed based on the risk of
ischemia and bleeding in clinical setting. Furthermore, the ischemic and bleeding risk may be
different among patients with ACS. Therefore, decision regarding DAPT duration are more
complicated and need a shared decision to achieve better net clinical outcome. [19]
Our study demonstrated that short-duration (�6 months) DAPT was associated with a
similar rate of net adverse cardiovascular and clinical events in patients with ACS (including
MI) treated with second-generation DESs. Landmark analysis showed no divergence of the
curves for primary endpoint after 6 months following stent implantation between short-dura-
tion and standard-duration DAPT. The cumulative low incidence of stent thrombosis or MI
after second-generation DES implantation might have contributed to these results, suggesting
that short-duration (�6 months) DAPT might be applied for selected patients with low ische-
mic risk of ACS after second-generation DESs. Although some discrepant results were
observed regarding the efficacy and safety of long-term DAPT after DES implantation, recent
PCI guidelines indicate that 6-month DAPT is recommended after second-generation DES
implantation for patients with ACS and those with a higher bleeding risk. [1] The current
pooled analysis provides useful information regarding optimal DAPT duration in patients
with ACS after second-generation DES implantation, although our results should be inter-
preted with caution according to each clinical situation.
In a subgroup analysis, significant interaction was shown between chronic kidney disease
and duration of DAPT. Chronic kidney disease is well known to be a risk factor for both ische-
mic and bleeding clinical events. [20] For net clinical and cardiovascular benefit, standard
duration of DAPT could be inferior compared to short-duration of DAPT.
Based on PRECISE-DAPT score, ‘very low’ bleeding risk group showed lower net clinical
and cardiovascular events in standard-duration of DAPT compared to short-duration of
DAPT in our study. These results might suggest longer DAPT for low bleeding risk with high
ischemic risk group such as ACS. But, overall borderline interaction with the PRECISE-DAPT
score indicated that a personalized approach might be the best option to optimize a clinical
outcome.
Current guideline recommended to decide duration of DAPT based on bleeding risk score
system that is not enough to say ‘personalized DAPT’. [1] To develop a prediction model more
accurately, in additional to traditional risk factors such as diabetes, complexity of coronary
DAPT after 2nd generation DES in ACS
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disease, epigenetic novel biomarkers may play a role to differentiate an inter-individual platelet
reactivity, disease susceptibility or response to therapy. [21] For an association between a plate-
let activity and diabetes, several studies indicated an interaction between DAPT duration and
diabetes in terms of clinical outcomes in first-generation DESs. [22] However, this interaction
was not shown in second-generation DESs. [3] In our subgroup analysis, there was a no signif-
icant difference in clinical event between patient with diabetes and non-diabetes. Although
diabetes is well known to be associated with an increased platelet activity, [23] more investiga-
tion is needed to prove whether diabetes itself could interact with DAPT duration for clinical
events after second-generation DES implantation.
Coronary artery disease is complex and broad-spectrum disease that many factors should
be taken into consideration. However, prediction model based on traditional mathematical
model is too complex to apply in clinical practice. Artificial neural networks and sustainable
machine learning systems might be helpful in solving dilemmas of optimal DAPT duration
raised by our meta-analysis. [24] However, more advanced development and validation are
need to apply for clinical practice.
Study limitation
This study has limitations. First, sample size of the study population might be not sufficient to
evaluate the safety of short-duration DAPT compared to longer-duration DAPT in terms of
hard clinical endpoints such as death, MI, or stent thrombosis. Second, all 3 trials were open-
label and not placebo-controlled studies; however, the possibility of bias was minimized in
each trial by using precisely-defined criteria for the primary endpoint, blinding the adjudica-
tion by event-adjudication committee members, and analyzing the data using intention-to-
treat methodology. Third, short-duration DAPT was 3 months (RESET) or 6 months (Excel-
lent and XPL-IVUS), and the Endeavor zotarolimus-eluting stent was included in the 3-month
DAPT group in the RESET study. Fourth, clopidogrel was used with aspirin as DAPT in all 3
trials, so we could not evaluate the effects of DAPT duration for other antiplatelet agents, such
as ticagrelor or prasugrel. Fifth, 1 year of clinical follow-up may not be sufficient to assess late
outcomes, especially very late stent thrombosis. Nevertheless, only a few existing clinical stud-
ies have been performed with adequate number of populations for optimal duration of DAPT
in ACS patients. In this perspective, our pooled patient-level analysis may provide an insight
to how to apply an optimal duration of DAPT in current DES era with reasonable number of
patient population with ACS.
Conclusions
In patient-level pooled analysis, short-duration (�6 months) DAPT showed no difference in
incidence of net adverse cardiovascular and clinical events, including cardiac death, MI, stent
thrombosis, stroke or major bleeding at 12 months after second-generation DES implantation
in patients with ACS compared with standard-duration (�12 months) DAPT. Composite of
cardiac death, MI or stent thrombosis or each component also did not differ according to
DAPT duration. These findings should be confirmed with large randomized clinical trials.
Supporting information
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